Mortality risk factors for 152 1-year survivors of HSCT for aplastic anemia
| . | Univariate . | Multivariate . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Diagnosis | ||||
| Acquired AA | 1.0 | 1.0 | ||
| Fanconi anemia | 4.01 (1.3-12) | .03 | 4.43 (1.4-14) | .03 |
| Previous acute GVHD | ||||
| No | 1.0 | |||
| Yes | 2.04 (0.8-5.3) | .15 | ||
| Previous chronic GVHD | ||||
| No | 1.0 | 1.0 | ||
| Yes | 3.15 (1.3-7.9) | .02 | 3.73 (1.4-10) | .02 |
| Sex | ||||
| Female | 1.0 | |||
| Male | 1.56 (0.6-4.0) | .34 | ||
| Prophylaxis | ||||
| CSP | 1.0 | |||
| Combination | 1.63 (0.5-5.3) | .41 | ||
| Diagnosis to Tx | ||||
| 0-1 yr | 1.0 | |||
| 1 yr | 1.74 (0.5–6.1) | .41 | ||
| Regimen | ||||
| CY | 1.0 | |||
| TBI low | 5.62 (1.0-32) | |||
| TBI high | 0 (undefined) | .05 | ||
| Donor | ||||
| Matched related | 1.0 | |||
| Mismatch related | 0 (undefined) | |||
| Unrelated | 2.92 (0.6-14) | .28 | ||
| Age at HSCT, y | ||||
| 0-6 | 1.0 | |||
| 7-12 | 1.31 (0.3-5.3) | |||
| 13-17 | 1.95 (0.5-7.1) | .52 | ||
| . | Univariate . | Multivariate . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Diagnosis | ||||
| Acquired AA | 1.0 | 1.0 | ||
| Fanconi anemia | 4.01 (1.3-12) | .03 | 4.43 (1.4-14) | .03 |
| Previous acute GVHD | ||||
| No | 1.0 | |||
| Yes | 2.04 (0.8-5.3) | .15 | ||
| Previous chronic GVHD | ||||
| No | 1.0 | 1.0 | ||
| Yes | 3.15 (1.3-7.9) | .02 | 3.73 (1.4-10) | .02 |
| Sex | ||||
| Female | 1.0 | |||
| Male | 1.56 (0.6-4.0) | .34 | ||
| Prophylaxis | ||||
| CSP | 1.0 | |||
| Combination | 1.63 (0.5-5.3) | .41 | ||
| Diagnosis to Tx | ||||
| 0-1 yr | 1.0 | |||
| 1 yr | 1.74 (0.5–6.1) | .41 | ||
| Regimen | ||||
| CY | 1.0 | |||
| TBI low | 5.62 (1.0-32) | |||
| TBI high | 0 (undefined) | .05 | ||
| Donor | ||||
| Matched related | 1.0 | |||
| Mismatch related | 0 (undefined) | |||
| Unrelated | 2.92 (0.6-14) | .28 | ||
| Age at HSCT, y | ||||
| 0-6 | 1.0 | |||
| 7-12 | 1.31 (0.3-5.3) | |||
| 13-17 | 1.95 (0.5-7.1) | .52 | ||
CI indicates confidence interval; CSP, cyclosporine; CY, cyclophosphamide; HR, hazard ratio; TBI, total body irradiation; and Tx, transplantation